Literature DB >> 11729003

Maintenance immunosuppression in the renal transplant recipient: an overview.

R S Gaston1.   

Abstract

Managing maintenance immunosuppressive regimens after kidney transplantation is often challenging and confusing, requiring careful attention to efficacy, dosing, adverse effects, and costs of multiple medications. Most protocols combine a primary immunosuppressant (cyclosporine or tacrolimus) with one or two adjunctive agents (azathioprine, mycophenolate mofetil, sirolimus, corticosteroids). Avoiding drug-drug interactions is a major part of effective immunosuppressant management, and special situations (eg, pregnancy, intravenous dosing, caring for minority patients) can prove especially daunting. This review summarizes available data regarding current practices in maintenance immunosuppression, emphasizing issues that arise in day-to-day management of renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11729003     DOI: 10.1053/ajkd.2001.28923

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

1.  Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.

Authors:  Steffen Bauer; Elke Störmer; Andreas Johne; Hagen Krüger; Klemens Budde; Hans-Hellmut Neumayer; Ivar Roots; Ingrid Mai
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.

Authors:  Jong Joo Lee; Mee Kum Kim; Won Ryang Wee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-21       Impact factor: 3.117

Review 3.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A.

Authors:  Anne-Kristina Frobel; Mats O Karlsson; Janne T Backman; Kalle Hoppu; Erik Qvist; Paula Seikku; Hannu Jalanko; Christer Holmberg; Ron J Keizer; Samuel Fanta; Siv Jönsson
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 5.  Contraception for renal transplant recipients in the Republic of Ireland : a review.

Authors:  T Ramhendar; P Byrne
Journal:  Ir J Med Sci       Date:  2013-03-11       Impact factor: 1.568

6.  Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.

Authors:  Yuen Yi Hon; Christine E Chamberlain; David E Kleiner; Michael S Ring; Douglas A Hale; Allan D Kirk; Roslyn B Mannon
Journal:  Clin Transplant       Date:  2010 Jul-Aug       Impact factor: 2.863

7.  ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients.

Authors:  Ya-tong Zhang; Li-ping Yang; Hong Shao; Ke-xin Li; Chun-hua Sun; Lu-wen Shi
Journal:  Br J Clin Pharmacol       Date:  2008-08       Impact factor: 4.335

Review 8.  Immunosuppression in pregnancy: choices for infant and maternal health.

Authors:  Vincent T Armenti; Michael J Moritz; Elyce H Cardonick; John M Davison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Tacrolimus: a further update of its use in the management of organ transplantation.

Authors:  Lesley J Scott; Kate McKeage; Susan J Keam; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Management of children after renal transplantation: highlights for general pediatricians.

Authors:  Keith K Lau; Lucy Giglia; Howard Chan; Anthony K Chan
Journal:  Transl Pediatr       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.